심리적도박 | Cases and Studies in Pathological Gambling | 游戏设计
- date : 2015-05-20 01:10|hit : 1972
-
- Article] Predicting response to opiate antagonists and placebo in the treatment of pathological gambling
-
DocNo of ILP: 3581
Doc. Type: Article
Title: Predicting response to opiate antagonists and placebo in the treatment of pathological gambling
Authors: Grant, JE; Kim, SW; Hollander, E; Potenza, MN
Full Name of Authors: Grant, Jon E.; Kim, Suck Won; Hollander, Eric; Potenza, Marc N.
Keywords by Author: opiate antagonists; impulsivity; impulse control disorders; addiction; pharmacotherapy; placebo
Keywords Plus: IMPULSE CONTROL DISORDERS; VENTRAL TEGMENTAL AREA; DOUBLE-BLIND; ALCOHOL DEPENDENCE; CONTROLLED-TRIAL; NALTREXONE; VULNERABILITY; NALMEFENE; GAMBLERS; RELEASE
Abstract: Rationale Although opiate antagonists have shown promise in the treatment of pathological gambling (PG), individual responses vary. No studies have systematically examined predictors of medication treatment outcome in PG. Understanding clinical variables related to treatment outcome should help generate treatment algorithms for PG. Objective We sought to identify clinical variables associated with treatment outcome in PG subjects receiving opiate antagonists. Materials and Methods Two hundred eighty-four subjects [137 (48.2%) women] with DSM-IV PG were treated in one of two double-blind placebo-controlled trials (16 weeks of nalmefene or 18 weeks of naltrexone). Gambling severity was assessed with the Yale Brown Obsessive Compulsive Scale Modified for Pathological Gambling (PG-YBOCS) with positive response defined as >= 35% reduction in PG-YBOCS score for at least 1 month by study endpoint. Depression, anxiety, and psychosocial functioning were included in stepwise logistic regression analyses designed to identify clinical factors independently associated with treatment response. Results The clinical variable most strongly associated with a positive response to an opiate antagonist was a positive family history of alcoholism (p=0.006). Among individuals receiving higher doses of opiate antagonists (i.e., nalmefene 50 or 100 mg/day or naltrexone 100 or 150 mg/day), intensity of gambling urges (PG-YBOCS urge subscale) was associated with a positive response on a trend level (p=0.036). Among individuals receiving placebo, younger age was associated, on a trend level, with positive treatment outcome (p=0.012). Conclusions A family history of alcoholism appears to predict response to an opiate antagonist in PG. Future research is needed to identify specific factors (e.g., genetic) mediating favorable responses.
Cate of OECD: Basic medicine
Year of Publication: 2008
Business Area: gamble
Detail Business: gamble
Country: USA
Study Area:
Name of Journal: PSYCHOPHARMACOLOGY
Language: English
Country of Authors: [Grant, Jon E.; Kim, Suck Won] Univ Minnesota, Sch Med, Dept Psychiat, Minneapolis, MN 55454 USA; [Hollander, Eric] Mt Sinai Sch Med, Dept Psychiat, New York, NY USA; [Potenza, Marc N.] Yale Univ, Sch Med, Connecticut Mental Hlth Ctr, New Haven, CT 06508 USA; [Potenza, Marc N.] Yale Univ, Sch Med, VA Connecticut Healthcare Syst, New Haven, CT USA; [Potenza, Marc N.] Yale Univ, Sch Med, Dept Psychiat, New Haven, CT USA; [Potenza, Marc N.] Yale Univ, Sch Med, Ctr Child Study, New Haven, CT 06510 USA
Press Adress: Grant, JE (reprint author), Univ Minnesota, Sch Med, Dept Psychiat, 2450 Riverside Ave, Minneapolis, MN 55454 USA.
Email Address: grant045@umn.edu
Citaion:
Funding: Career Development Award; NIMH [R21-MH065920]
Lists of Citation: Anton RF, 2006, JAMA-J AM MED ASSOC, V295, P2003, DOI 10.1001/jama.295.17.2003; Anton RF, 1999, AM J PSYCHIAT, V156, P1758; Blanco C, 2001, Semin Clin Neuropsychiatry, V6, P167, DOI 10.1053/scnp.2001.22921; Brewer JA, 2008, BIOCHEM PHARMACOL, V75, P63, DOI 10.1016/j.bcp.2007.06.043; BROEKKAMP CL, 1979, PHARMACOL BIOCHEM BE, V11, P289, DOI 10.1016/0091-3057(79)90137-0; Chambers RA, 2003, AM J PSYCHIAT, V160, P1041, DOI 10.1176/appi.ajp.160.6.1041; De la Fuente-Fernandez R, 2006, J NEURAL TRANSM-SUPP, P415; Dell'Osso B, 2006, EUR ARCH PSY CLIN N, V256, P464, DOI 10.1007/s00406-006-0668-0; First M. B, 1995, STRUCTURED CLIN INTE; Grant J. E., 2007, GUIDE TREATMENTS WOR, P561; Grant JE, 2008, J CLIN PSYCHIAT, V69, P783; Grant JE, 2006, AM J PSYCHIAT, V163, P303, DOI 10.1176/appi.ajp.163.2.303; HAMILTON M, 1960, J NEUROL NEUROSUR PS, V23, P56, DOI 10.1136/jnnp.23.1.56; HAMILTON M, 1959, BRIT J MED PSYCHOL, V32, P50; Hollander E, 2000, BIOL PSYCHIAT, V47, P813, DOI 10.1016/S0006-3223(00)00241-9; Hollander E, 2005, AM J PSYCHIAT, V162, P137, DOI 10.1176/appi.ajp.162.1.137; Kim SW, 2001, BIOL PSYCHIAT, V49, P914, DOI 10.1016/S0006-3223(01)01079-4; KOSTEN TR, 1989, LIFE SCI, V44, P887, DOI 10.1016/0024-3205(89)90589-4; Krishnan-Sarin S, 2007, BIOL PSYCHIAT, V62, P694, DOI 10.1016/j.biopsych.2006.11.018; Krystal JH, 2001, NEW ENGL J MED, V345, P1734, DOI 10.1056/NEJMoa011127; LESIEUR HR, 1987, AM J PSYCHIAT, V144, P1184; MARTIN WR, 1973, ARCH GEN PSYCHIAT, V28, P784; Mason BJ, 1999, ARCH GEN PSYCHIAT, V56, P719, DOI 10.1001/archpsyc.56.8.719; MATTHEWS RT, 1984, NEUROSCIENCE, V11, P617, DOI 10.1016/0306-4522(84)90048-4; Monterosso JR, 2001, AM J ADDICTION, V10, P258; Montgomery SA, 1999, EUR NEUROPSYCHOPHARM, V9, P271, DOI 10.1016/S0924-977X(98)00050-9; O'Brien CP, 2005, AM J PSYCHIAT, V162, P1423, DOI 10.1176/appi.ajp.162.8.1423; Oslin DW, 2003, NEUROPSYCHOPHARMACOL, V28, P1546, DOI 10.1038/sj.npp.1300219; Pallanti S, 2005, J GAMBL STUD, V21, P431, DOI 10.1007/s10899-005-5557-3; Ray LA, 2007, ARCH GEN PSYCHIAT, V64, P1069, DOI 10.1001/archpsyc.64.9.1069; Rosner B., 1995, FUNDAMENTALS BIOSTAT; Scott DJ, 2007, NEURON, V55, P325, DOI 10.1016/j.neuron.2007.06.028; Sheehan D, 1983, ANXIETY DIS; Slutske WS, 2000, ARCH GEN PSYCHIAT, V57, P666, DOI 10.1001/archpsyc.57.7.666; VOLPICELLI JR, 1992, ARCH GEN PSYCHIAT, V49, P876
Number of Citaion: 35
Publication: SPRINGER
City of Publication: NEW YORK
Address of Publication: 233 SPRING ST, NEW YORK, NY 10013 USA
ISSN: 0033-3158
29-Character Source Abbreviation: PSYCHOPHARMACOLOGY
ISO Source Abbreviation: Psychopharmacology
Volume: 200
Version: 4
Start of File: 521
End of File: 527
DOI: 10.1007/s00213-008-1235-3
Number of Pages: 7
Web of Science Category: Neurosciences; Pharmacology & Pharmacy; Psychiatry
Subject Category: Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry
Document Delivery Number: 353PD
Unique Article Identifier: WOS:000259579100007
[이 게시물은 HyeJung Mo…님에 의해 2015-05-20 15:31:15 GAMBLING에서 이동 됨]
- reply : 0
-
- list
-
- prev
- next